These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 14527772)

  • 1. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance.
    Marchese A; Gualco L; Debbia EA; Schito GC; Schito AM
    Int J Antimicrob Agents; 2003 Oct; 22 Suppl 2():53-9. PubMed ID: 14527772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
    Demir T; Buyukguclu T
    Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
    Khan IU; Mirza IA; Ikram A; Ali S; Hussain A; Ghafoor T
    J Coll Physicians Surg Pak; 2014 Dec; 24(12):914-7. PubMed ID: 25523727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study.
    García-Rodríguez JA; Trujillano Martín I; Baquero F; Cisterna R; Gobernado M; Liñares F; Martín-Luengo F; Piédrola G
    J Chemother; 1997 Dec; 9(6):394-402. PubMed ID: 9491838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study.
    Fajfr M; Louda M; Paterová P; Ryšková L; Pacovský J; Košina J; Žemličková H; Broďák M
    BMC Urol; 2017 Apr; 17(1):33. PubMed ID: 28446177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.
    Schito GC; Naber KG; Botto H; Palou J; Mazzei T; Gualco L; Marchese A
    Int J Antimicrob Agents; 2009 Nov; 34(5):407-13. PubMed ID: 19505803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials.
    Samonis G; Maraki S; Rafailidis PI; Kapaskelis A; Kastoris AC; Falagas ME
    Future Microbiol; 2010 Jun; 5(6):961-70. PubMed ID: 20521939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
    Gualco L; Schito AM; Schito GC; Marchese A
    Int J Antimicrob Agents; 2007 Jun; 29(6):679-87. PubMed ID: 17363225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Antananarivo, Madagascar.
    Randrianirina F; Soares JL; Carod JF; Ratsima E; Thonnier V; Combe P; Grosjean P; Talarmin A
    J Antimicrob Chemother; 2007 Feb; 59(2):309-12. PubMed ID: 17138569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully.
    Patwardhan V; Singh S
    Int Urol Nephrol; 2017 Sep; 49(9):1637-1643. PubMed ID: 28616818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal
    Ito R; Mustapha MM; Tomich AD; Callaghan JD; McElheny CL; Mettus RT; Shanks RMQ; Sluis-Cremer N; Doi Y
    mBio; 2017 Aug; 8(4):. PubMed ID: 28851843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands?
    Knottnerus BJ; Nys S; Ter Riet G; Donker G; Geerlings SE; Stobberingh E
    J Antimicrob Chemother; 2008 Aug; 62(2):356-9. PubMed ID: 18424789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fosfomycin: mechanisms and the increasing prevalence of resistance.
    Aghamali M; Sedighi M; Zahedi Bialvaei A; Mohammadzadeh N; Abbasian S; Ghafouri Z; Kouhsari E
    J Med Microbiol; 2019 Jan; 68(1):11-25. PubMed ID: 30431421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fosfomycin trometamol on bacterial adhesion in comparison with other chemotherapeutic agents.
    Carlone NA; Borsotto M; Cuffini AM; Savoia D
    Eur Urol; 1987; 13 Suppl 1():86-91. PubMed ID: 3552703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to oral antibiotics in 4569 Gram-negative rods isolated from urinary tract infection in children.
    Calzi A; Grignolo S; Caviglia I; Calevo MG; Losurdo G; Piaggio G; Bandettini R; Castagnola E
    Eur J Pediatr; 2016 Sep; 175(9):1219-1225. PubMed ID: 27558493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens.
    Mezzatesta ML; La Rosa G; Maugeri G; Zingali T; Caio C; Novelli A; Stefani S
    Int J Antimicrob Agents; 2017 Jun; 49(6):763-766. PubMed ID: 28390962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: a prospective study.
    Sahni RD; Balaji V; Varghese R; John J; Tansarli GS; Falagas ME
    Future Microbiol; 2013 May; 8(5):675-80. PubMed ID: 23642120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.